{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:32:19Z","timestamp":1782325939304,"version":"3.54.5"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0058949","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T19:45:26Z","timestamp":1363290326000},"page":"e58949","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using 64Cu-bevacizumab ImmunoPET"],"prefix":"10.1371","volume":"8","author":[{"given":"Albert J.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Arbeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"D Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis","volume":"146","author":"M Potente","year":"2011","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"P Carmeliet","year":"2011","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrc2346","article-title":"Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer","volume":"8","author":"RK Jain","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"M Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/path.2689","article-title":"VHL and HIF signalling in renal cell carcinogenesis","volume":"221","author":"MM Baldewijns","year":"2010","journal-title":"J Pathol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.critrevonc.2005.12.003","article-title":"Regulation of angiogenesis by hypoxia-inducible factor 1","volume":"59","author":"K Hirota","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.1073\/pnas.1101321108","article-title":"VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting","volume":"108","author":"S Oladipupo","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"LM Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1042\/BJ20071518","article-title":"TOR regulation of AGC kinases in yeast and mammals","volume":"410","author":"E Jacinto","year":"2008","journal-title":"Biochem J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"947858","DOI":"10.1155\/2011\/947858","article-title":"PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors","volume":"2011","author":"F Dituri","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4161\/cbt.10.7.13247","article-title":"Signaling pathways in renal cell carcinoma","volume":"10","author":"G Banumathy","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1042\/BST0390446","article-title":"Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis","volume":"39","author":"Y Huo","year":"2011","journal-title":"Biochem Soc Trans"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/cbr.2008.0527","article-title":"18F-FDG PET\/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study","volume":"24","author":"L Vercellino","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin","volume":"22","author":"CC Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"AK Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1593\/tlo.09277","article-title":"Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals","volume":"3","author":"T O\u2019Reilly","year":"2010","journal-title":"Transl Oncol"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Barlow AD, Xie J, Moore CE, Campbell SC, Shaw JA, <etal>et al<\/etal>.. (2012) Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). Diabetologia.","DOI":"10.1007\/s00125-012-2475-7"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"M Guba","year":"2002","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"RJ Motzer","year":"2008","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"BI Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4161\/cc.11.3.19096","article-title":"mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors","volume":"11","author":"Y Zhang","year":"2012","journal-title":"Cell Cycle"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/jcp.22647","article-title":"Therapeutic resistance resulting from mutations in Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR signaling pathways","volume":"226","author":"JA McCubrey","year":"2011","journal-title":"J Cell Physiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","article-title":"Mechanisms of mTOR inhibitor resistance in cancer therapy","volume":"6","author":"JS Carew","year":"2011","journal-title":"Target Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.hoc.2011.05.003","article-title":"Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions","volume":"25","author":"S Chowdhury","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-10-1088","article-title":"VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment","volume":"71","author":"WB Nagengast","year":"2011","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.25409","article-title":"PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A\u201d-DTPA-bevacizumab","volume":"128","author":"TK Nayak","year":"2011","journal-title":"Int J Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1349-7006.2010.01763.x","article-title":"Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts","volume":"102","author":"B Paudyal","year":"2011","journal-title":"Cancer Sci"},{"key":"ref29","first-page":"1","article-title":"Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab","volume":"2","author":"Y Zhang","year":"2012","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0969-8051(96)00157-6","article-title":"Efficient production of high specific activity 64Cu using a biomedical cyclotron","volume":"24","author":"DW McCarthy","year":"1997","journal-title":"Nucl Med Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MNM.0b013e3283419523","article-title":"PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma","volume":"32","author":"K Sadri","year":"2011","journal-title":"Nucl Med Commun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/bc2002665","article-title":"Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates","volume":"22","author":"S Ait-Mohand","year":"2011","journal-title":"Bioconjug Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"KE O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"DD Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","article-title":"Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST","volume":"22","author":"MJ Ratain","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11523-010-0146-5","article-title":"Targeted therapies in renal cell cancer: recent developments in imaging","volume":"5","author":"AA van der Veldt","year":"2010","journal-title":"Target Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1101\/gad.1756509","article-title":"Tumor suppressors and cell metabolism: a recipe for cancer growth","volume":"23","author":"RG Jones","year":"2009","journal-title":"Genes Dev"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-07-1824","article-title":"Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma","volume":"14","author":"LH Wei","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"RJ Amato","year":"2009","journal-title":"Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1593\/tlo.10127","article-title":"Anti-Angiogenic\/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG\/FLT-PET","volume":"3","author":"M Honer","year":"2010","journal-title":"Transl Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1200\/JCO.2003.04.073","article-title":"F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma","volume":"21","author":"NS Majhail","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/MNM.0b013e32832ee93b","article-title":"Molecular PET and PET\/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation","volume":"30","author":"T Barwick","year":"2009","journal-title":"Nucl Med Commun"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/cbr.2010.0776","article-title":"Positive progress in immunoPET\u2013not just a coincidence","volume":"25","author":"KE McCabe","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4155\/fmc.11.14","article-title":"The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86","volume":"3","author":"OF Ikotun","year":"2011","journal-title":"Future Medicinal Chemistry"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1189\/jlb.1107762","article-title":"Macrophages define the invasive microenvironment in breast cancer","volume":"84","author":"JW Pollard","year":"2008","journal-title":"J Leukoc Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcdb.2009.11.017","article-title":"Origin and function of tumor stroma fibroblasts","volume":"21","author":"G Xouri","year":"2010","journal-title":"Semin Cell Dev Biol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1158\/0008-5472.CAN-08-0925","article-title":"Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells","volume":"68","author":"F Shojaei","year":"2008","journal-title":"Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-337-0_1","article-title":"Targeting cancer with small-molecular-weight kinase inhibitors","volume":"795","author":"D Fabbro","year":"2012","journal-title":"Methods Mol Biol"},{"key":"ref49","first-page":"1996","article-title":"Assessment of tumor response to tyrosine kinase inhibitors","volume":"17","author":"A Lowery","year":"2012","journal-title":"Front Biosci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc2824","article-title":"Translational control in cancer","volume":"10","author":"D Silvera","year":"2010","journal-title":"Nat Rev Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0058949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:08:51Z","timestamp":1588964931000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0058949"}},"subtitle":[],"editor":[{"given":"Alexander J.","family":"Annala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0058949","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}